{"prompt": "['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'Collect and review Subject Diary.', 'Assess treatment compliance.', 'Allocate study treatment through the IWRS.', '-', 'In addition to study treatment for Visit 9 (Week 88) administration, subjects will', 'receive 1 vial or 1 PFS of OKZ for each dose that is scheduled to be administered', 'prior to Visit 10 (EoT/Week 106).', 'Administer study treatment.', '5.4.2', 'Visit 10/End of Treatment (2 Weeks After the Last Dose of the Study', 'Treatment)/(Week 106)', 'Visit 10 (EoT/Week 106) will be performed at Week 106 for subjects who complete all', 'scheduled study visits or 2 weeks after the last dose of study treatment for subjects who', 'discontinue study treatment prematurely.', 'The following assessments will be performed at Visit 10 (EoT/Week 106) for all subjects:', 'Administer Patient Global Assessment of Disease Activity (VAS).', 'Administer Patient Assessment of Pain (VAS).', 'Administer HAQ-DI.', 'Administer SF-36, EQ-5D, FACIT-Fatigue, and WPS-RA.', 'Perform joint counts (Independent Joint Assessment).', 'Assess Treatment Response', 'Administer Physician Global Assessment (VAS).', 'Record details of contraceptive history/status.', 'Record concomitant medications and concomitant non-drug therapies.', 'Administer TB risk questionnaire.', 'Assess AEs/SAEs (and injection site reactions) that have occurred since the previous', 'visit.', 'Record weight.', 'Record vital signs.', 'Amendment 2: 06 March 2019', '70', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'Perform complete physical examination.', 'Perform CV risk assessment.', 'Perform 12-lead ECG.', 'Perform chest X-ray.', '- Chest X-ray need not be conducted if performed and evaluated within 8 weeks prior', 'to Visit 10 (EoT/Week 106), and if the films or images are available and included in', \"the subject's source documents.\", 'Collect samples for INR, aPTT, and fibrinogen.', 'Measure ESR.', 'Collect sample to measure CRP level.', 'Collect samples for lipid panel and CV risk panel.', 'Collect samples for chemistry panel, hematology assessments, ANAs, and dsDNA', 'antibodies.', 'Collect sample for HbA1c assessment (subjects with confirmed diabetes mellitus only).', 'Perform IGRA testing only for subjects who had a negative IGRA result at the', 'previous assessments (including Week 22 assessment of the core study) unless another', 'approach is required by local practice. If results are indeterminate, the IGRA can be', 'repeated once.', 'Collect sample for analysis of ADAs.', 'Perform urine pregnancy test for females of childbearing potential only.', 'Collect sample for urinalysis.', 'Collect and review Subject Diary.', 'Assess treatment compliance.', 'Change subject status in the IWRS', 'Amendment 2: 06 March 2019', '71', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', '5.4.3', 'Safety Follow-Up: Visits SFU-1, SFU-2, and SFU-3', '5.4.3.1', 'Visit SFU-1 (Week 108 or 4 Weeks after the Last Dose of the Study Treatment)', 'The following assessments will be conducted 4 weeks after the last dose of the study', 'treatment:', 'Record AEs/SAEs.', 'Record details of contraceptive history/status.', 'Record concomitant medications and concomitant non-drug therapies.', 'Record weight.', 'Record vital signs.', 'Perform partial physical examination.', 'Measure ESR.', 'Collect sample to measure CRP level.', 'Collect samples for chemistry panel and hematology assessments.', 'Perform urine pregnancy test for females of childbearing potential only.', '5.4.3.2', 'Visit SFU-2 (Week 112 or 8 Weeks after the Last Dose of the Study Treatment)', 'The following assessments will be conducted 8 weeks after the last dose of the study', 'treatment:', 'Record AEs/SAEs.', 'Record details of contraceptive history/status.', 'Record concomitant medications and concomitant non-drug therapies.', 'Administer TB risk questionnaire.', 'Record weight.', 'Record vital signs.', 'Perform partial physical examination.', 'Measure ESR.', 'Collect sample to measure CRP level.', 'Amendment 2: 06 March 2019', '72', 'Confidential']\n\n###\n\n", "completion": "END"}